Two new videos have been released in the OncLive TV series on carcinoid and neuroendocrine tumors (NETs), including pancreatic neuroendocrine tumors, and genetic syndromes that predispose people to develop pancreatic NETs such MEN1 (multiple endocrine neoplasia) and tuberous sclerosis. A panel of medical experts discusses “Techniques for Diagnosing Neuroendocrine Tumors” and “The Genetics Behind Familial Neuroendocrine Tumors” in the most recent videos.
The panel includes carcinoid/NET specialists Dr. Matthew Kulke (moderator, pictured below), Director of the Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber/Brigham and Women’s Cancer and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts; Dr. Rodney F. Pommier, Professor of Surgery and Surgical Oncologist, Oregon Health and Science University in Portland, Oregon; and Dr. James C. Yao, Associate Professor Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, Texas; as well as Dr. Pamela L. Kunz, Assistant Professor, Stanford School of Medicine in Stanford, California.
Please note: to see the videos below in a larger format, click on the YouTube logo in the bottom right corner of each video.
Techniques for Diagnosing Neuroendocrine Tumors focuses on the imaging techniques used for identifying NETs and locating the primary site. These include multiphasic contrast-enhanced CT, MRI, and octreotide scans. Dr. Pommier stresses that it is very important to identify the type of tumor as treatment options differ for carcinoid and pancreatic neuroendocrine tumors. Participation in clinical trials is also dependent upon the type of a patient’s tumor.
“There are some genetic syndromes that predispose people to get neuroendocrine tumors,” notes Dr. Kulke in The Genetics Behind Familial Neuroendocrine Tumors. Most of these are associated with pancreatic neuroendocrine tumors. According to Dr. Yao these syndromes include MEN1 (multiple endocrine neoplasia), tuberous sclerosis, neurofibromatosis, and Von Hippel-Lindau. Dr. Kulke says that genetic counseling is “key” for patients and family members diagnosed with these genetic syndromes since this counseling may guide screening and tumor detection.
To view the previous videos in the OncLive TV Neuroendocrine Tumor series, CLICK HERE.